Biogen publishes data on its Alzheimer's drug in a little-known journal - STAT

The key data that led to Aduhelm’s approval by the FDA have finally been published, more than two years after they were first described in a press release.

When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped in drama. The key data that led to Aduhelm’s approval by the Food and Drug Administration were f… [+191 chars]

full article...